PubMed

Gene expression patterns that predict sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer cell lines and human lung tumors.

Balko JM, Potti A, Saunders C, Stromberg A, Haura EB, Black EP.

BMC Genomics. 2006 Nov 10;7:289.PMID: 17096850 [PubMed - indexed for MEDLINE]Related articlesFree article

Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.

Helfrich BA, Raben D, Varella-Garcia M, Gustafson D, Chan DC, Bemis L, Coldren C, Barón A, Zeng C, Franklin WA, Hirsch FR, Gazdar A, Minna J, Bunn PA Jr.

Clin Cancer Res. 2006 Dec 1;12(23):7117-25.PMID: 17145836 [PubMed - indexed for MEDLINE]Related articlesFree article

Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.

Chang JW, Liu HP, Hsieh MH, Fang YF, Hsieh MS, Hsieh JJ, Chiu YT, Tsai HY, Chen YH, Chen YT, Hsu HY, Chen YT, Tsai SF, Chen YR, Hsi BL, Huang SF.

Lung Cancer. 2008 Sep;61(3):328-39. Epub 2008 Mar 4.PMID: 18304690 [PubMed - indexed for MEDLINE]Related articles

Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.

Yauch RL, Januario T, Eberhard DA, Cavet G, Zhu W, Fu L, Pham TQ, Soriano R, Stinson J, Seshagiri S, Modrusan Z, Lin CY, O'Neill V, Amler LC.

Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8686-98.PMID: 16361555 [PubMed - indexed for MEDLINE]Related articlesFree article

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68.PMID: 18927285 [PubMed - indexed for MEDLINE]Related articlesFree article

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.

PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680.PMID: 17973572 [PubMed - indexed for MEDLINE]Related articlesFree article

Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.

Zhang W, Stabile LP, Keohavong P, Romkes M, Grandis JR, Traynor AM, Siegfried JM.

J Thorac Oncol. 2006 Sep;1(7):635-47.PMID: 17409930 [PubMed - indexed for MEDLINE]Related articles

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer.

Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S.

Lancet Oncol. 2008 Oct;9(10):962-72. Epub 2008 Sep 17. Review.PMID: 18804418 [PubMed - indexed for MEDLINE]Related articles

Tumor dependence on the EGFR signaling pathway expressed by the p-EGFR:p-AKT ratio predicts erlotinib sensitivity in human non-small cell lung cancer (NSCLC) cells expressing wild-type EGFR gene.

Li T, Ling YH, Perez-Soler R.

J Thorac Oncol. 2008 Jun;3(6):643-7.PMID: 18520805 [PubMed - indexed for MEDLINE]Related articles

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.

Cappuzzo F, Hirsch FR, Rossi E, Bartolini S, Ceresoli GL, Bemis L, Haney J, Witta S, Danenberg K, Domenichini I, Ludovini V, Magrini E, Gregorc V, Doglioni C, Sidoni A, Tonato M, Franklin WA, Crino L, Bunn PA Jr, Varella-Garcia M.

J Natl Cancer Inst. 2005 May 4;97(9):643-55.PMID: 15870435 [PubMed - indexed for MEDLINE]Related articlesFree article

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.PMID: 15118073 [PubMed - indexed for MEDLINE]Related articlesFree article

Ovarian carcinoma as a surrogate tumor for lung adenocarcinomas in evaluating the chemo-stability of a gene expression signature.

Balko JM, Black EP.

Cancer Biol Ther. 2009 Jan;8(2):167-73. Epub 2009 Feb 4.PMID: 19029813 [PubMed - indexed for MEDLINE]Related articles

Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.

Bai H, Mao L, Wang HS, Zhao J, Yang L, An TT, Wang X, Duan CJ, Wu NM, Guo ZQ, Liu YX, Liu HN, Wang YY, Wang J.

J Clin Oncol. 2009 Jun 1;27(16):2653-9. Epub 2009 May 4.PMID: 19414683 [PubMed - indexed for MEDLINE]Related articles

An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).

Ferrer-Soler L, Vazquez-Martin A, Brunet J, Menendez JA, De Llorens R, Colomer R.

Int J Mol Med. 2007 Jul;20(1):3-10. Review.PMID: 17549382 [PubMed - indexed for MEDLINE]Related articles

KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, Bekele BN, Herbst RS, Wistuba II.

Clin Cancer Res. 2007 May 15;13(10):2890-6.PMID: 17504988 [PubMed - indexed for MEDLINE]Related articlesFree article

The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.

Suzuki T, Nakagawa T, Endo H, Mitsudomi T, Masuda A, Yatabe Y, Sugiura T, Takahashi T, Hida T.

Lung Cancer. 2003 Oct;42(1):35-41.PMID: 14512185 [PubMed - indexed for MEDLINE]Related articles

Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.

Noro R, Gemma A, Kosaihira S, Kokubo Y, Chen M, Seike M, Kataoka K, Matsuda K, Okano T, Minegishi Y, Yoshimura A, Kudoh S.

BMC Cancer. 2006 Dec 6;6:277.PMID: 17150102 [PubMed - indexed for MEDLINE]Related articlesFree article

Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.

Coldren CD, Helfrich BA, Witta SE, Sugita M, Lapadat R, Zeng C, Barón A, Franklin WA, Hirsch FR, Geraci MW, Bunn PA Jr.

Mol Cancer Res. 2006 Aug;4(8):521-8.PMID: 16877703 [PubMed - indexed for MEDLINE]Related articlesFree article

Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.

Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B.

Cancer Res. 2006 Dec 1;66(23):11389-98.PMID: 17145885 [PubMed - indexed for MEDLINE]Related articlesFree article

Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).

Metro G, Finocchiaro G, Toschi L, Bartolini S, Magrini E, Cancellieri A, Trisolini R, Castaldini L, Tallini G, Crino L, Cappuzzo F.

Rev Recent Clin Trials. 2006 Jan;1(1):1-13. Review.PMID: 18393776 [PubMed - indexed for MEDLINE]Related articles